Medicines Co's Cangrelor clearly tops Plavix in pivotal trial

SAN FRANCISCO (Reuters) - The Medicines Co's experimental intravenous blood clot preventer Cangrelor, which is intended for use during angioplasty procedures, solidly outperformed commonly used Plavix in a pivotal late stage study, likely resurrecting the drug's prospects.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news